AR090349A1 - Terapia de combinacion para trastornos proliferativos, kit y uso - Google Patents
Terapia de combinacion para trastornos proliferativos, kit y usoInfo
- Publication number
- AR090349A1 AR090349A1 ARP130100844A ARP130100844A AR090349A1 AR 090349 A1 AR090349 A1 AR 090349A1 AR P130100844 A ARP130100844 A AR P130100844A AR P130100844 A ARP130100844 A AR P130100844A AR 090349 A1 AR090349 A1 AR 090349A1
- Authority
- AR
- Argentina
- Prior art keywords
- kit
- pharmaceutically acceptable
- acceptable salt
- combination therapy
- proliferative disorders
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 229940083338 MDM2 inhibitor Drugs 0.000 abstract 2
- 239000012819 MDM2-Inhibitor Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 abstract 1
- 229960003862 vemurafenib Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/402—1-aryl substituted, e.g. piretanide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612441P | 2012-03-19 | 2012-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090349A1 true AR090349A1 (es) | 2014-11-05 |
Family
ID=47884369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130100844A AR090349A1 (es) | 2012-03-19 | 2013-03-15 | Terapia de combinacion para trastornos proliferativos, kit y uso |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9216170B2 (https=) |
| EP (1) | EP2827859B1 (https=) |
| JP (1) | JP6141958B2 (https=) |
| KR (1) | KR101673731B1 (https=) |
| CN (2) | CN104114168A (https=) |
| AR (1) | AR090349A1 (https=) |
| AU (1) | AU2013203637B2 (https=) |
| BR (1) | BR112014018910A8 (https=) |
| CA (1) | CA2861056A1 (https=) |
| HK (1) | HK1201198A1 (https=) |
| MX (1) | MX2014010590A (https=) |
| NZ (1) | NZ626985A (https=) |
| RU (1) | RU2014141362A (https=) |
| SG (1) | SG11201404418QA (https=) |
| WO (1) | WO2013139724A1 (https=) |
| ZA (1) | ZA201405411B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008232709C1 (en) | 2007-03-28 | 2015-01-15 | President And Fellows Of Harvard College | Stitched polypeptides |
| KR20170058446A (ko) | 2010-08-13 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| AR088392A1 (es) | 2011-10-18 | 2014-05-28 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos |
| US20130245089A1 (en) | 2012-03-19 | 2013-09-19 | Hoffmann-La Roche Inc. | Method for administration |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| US20140200255A1 (en) | 2012-03-19 | 2014-07-17 | Brian Higgins | Method for administration |
| DK2884979T3 (da) | 2012-08-17 | 2019-09-02 | Hoffmann La Roche | Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| HRP20220718T1 (hr) * | 2013-11-11 | 2022-09-30 | Amgen Inc. | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka |
| WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| PT3077004T (pt) * | 2013-12-05 | 2020-04-16 | Hoffmann La Roche | Novo tratamento de combinação para a leucemia mieloide aguda (lma) |
| EP3459933B1 (en) * | 2014-04-15 | 2022-08-24 | F. Hoffmann-La Roche AG | Solid forms of a pharmaceutically active compound |
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| SG11201702175YA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
| WO2016049359A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| WO2016106357A1 (en) * | 2014-12-23 | 2016-06-30 | Millennnium Pharmaceuticals, Inc. | Combination of raf inhibitors and aurora kinase inhibitors |
| JP6564449B2 (ja) | 2015-02-20 | 2019-08-21 | 第一三共株式会社 | がんの併用治療法 |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| JP2018528217A (ja) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子 |
| WO2017066193A1 (en) | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Novel inhibitors of protein kinases |
| CA3007629A1 (en) | 2015-12-14 | 2017-06-22 | Red.Com, Llc | Modular digital camera and cellular phone |
| ES2928773T3 (es) | 2017-01-17 | 2022-11-22 | Heparegenix Gmbh | Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos |
| WO2020023502A1 (en) | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN110585433A (zh) * | 2019-09-27 | 2019-12-20 | 青岛大学 | Braf-v600e的抑制剂的应用及用于治疗甲状腺癌的药物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2550361C (en) | 2003-12-19 | 2014-04-29 | Prabha Ibrahim | Compounds and methods for development of ret modulators |
| CN102206216B (zh) | 2005-06-22 | 2014-11-12 | 普莱希科公司 | 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物 |
| CN101316823B (zh) | 2005-12-01 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物 |
| US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| KR101739994B1 (ko) | 2009-04-03 | 2017-05-25 | 에프. 호프만-라 로슈 아게 | 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도 |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| IN2012DN01403A (https=) | 2009-08-24 | 2015-06-05 | Genentech Inc | |
| US8779150B2 (en) | 2010-07-21 | 2014-07-15 | Hoffmann-La Roche Inc. | Processes for the manufacture of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1 H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| KR102021157B1 (ko) | 2011-04-01 | 2019-09-11 | 제넨테크, 인크. | Ａｋｔ 억제제 화합물 및 아비라테론의 조합물, 및 사용 방법 |
| PE20142312A1 (es) | 2011-10-28 | 2015-01-25 | Genentech Inc | Combinaciones terapeuticas y metodos para tratar el melanoma |
| US20130172375A1 (en) | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
-
2013
- 2013-02-05 US US13/759,458 patent/US9216170B2/en active Active
- 2013-03-15 AR ARP130100844A patent/AR090349A1/es unknown
- 2013-03-18 NZ NZ626985A patent/NZ626985A/en not_active IP Right Cessation
- 2013-03-18 MX MX2014010590A patent/MX2014010590A/es unknown
- 2013-03-18 CN CN201380009083.4A patent/CN104114168A/zh active Pending
- 2013-03-18 RU RU2014141362A patent/RU2014141362A/ru not_active Application Discontinuation
- 2013-03-18 CA CA2861056A patent/CA2861056A1/en not_active Abandoned
- 2013-03-18 EP EP13709468.6A patent/EP2827859B1/en active Active
- 2013-03-18 AU AU2013203637A patent/AU2013203637B2/en not_active Ceased
- 2013-03-18 JP JP2015500865A patent/JP6141958B2/ja not_active Expired - Fee Related
- 2013-03-18 SG SG11201404418QA patent/SG11201404418QA/en unknown
- 2013-03-18 HK HK15101803.8A patent/HK1201198A1/xx unknown
- 2013-03-18 BR BR112014018910A patent/BR112014018910A8/pt not_active IP Right Cessation
- 2013-03-18 WO PCT/EP2013/055522 patent/WO2013139724A1/en not_active Ceased
- 2013-03-18 CN CN201810155251.5A patent/CN108295063A/zh active Pending
- 2013-03-18 KR KR1020147026040A patent/KR101673731B1/ko not_active Expired - Fee Related
-
2014
- 2014-07-22 ZA ZA2014/05411A patent/ZA201405411B/en unknown
-
2015
- 2015-07-22 US US14/806,427 patent/US9486445B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014018910A8 (pt) | 2017-07-11 |
| JP2015510908A (ja) | 2015-04-13 |
| CA2861056A1 (en) | 2013-09-26 |
| CN108295063A (zh) | 2018-07-20 |
| RU2014141362A (ru) | 2016-05-10 |
| AU2013203637B2 (en) | 2016-07-07 |
| US20130245039A1 (en) | 2013-09-19 |
| EP2827859B1 (en) | 2018-10-17 |
| US20160051525A1 (en) | 2016-02-25 |
| HK1201198A1 (en) | 2015-08-28 |
| ZA201405411B (en) | 2019-09-25 |
| MX2014010590A (es) | 2014-09-18 |
| KR101673731B1 (ko) | 2016-11-07 |
| WO2013139724A1 (en) | 2013-09-26 |
| EP2827859A1 (en) | 2015-01-28 |
| AU2013203637A1 (en) | 2013-10-03 |
| US9486445B2 (en) | 2016-11-08 |
| SG11201404418QA (en) | 2014-10-30 |
| BR112014018910A2 (https=) | 2017-06-20 |
| JP6141958B2 (ja) | 2017-06-07 |
| KR20140130179A (ko) | 2014-11-07 |
| US9216170B2 (en) | 2015-12-22 |
| CN104114168A (zh) | 2014-10-22 |
| NZ626985A (en) | 2016-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| AR084691A1 (es) | Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel | |
| BR112016002287A2 (pt) | compostos terapeuticamente ativos e seus métodos de uso | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| BR112016000561B8 (pt) | Compostos terapeuticamente ativos, uso dos mesmos, composição farmacêutica e uso da mesma | |
| WO2015095819A3 (en) | Cancer treatment using combinations of erk and raf inhibitors | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| UY33984A (es) | Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| RU2018135973A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| CO6280574A2 (es) | Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| MX2019001850A (es) | Formulaciones para administracion oral de principios activos. | |
| ECSP19026973A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CL2022003039A1 (es) | Inhibidores de il4i1 y métodos de uso. | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| AR085132A1 (es) | Composiciones farmaceuticas para el tratamiento de glioma maligno | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| UY31826A (es) | Compuesto peptídico y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |